Koers Kanabo Group Plc London S.E.
Aandelen
SOP
GB00BYQCS703
Farmaceutische producten
Omzet 2022 | 603K 768K 709K | Omzet 2023 | 895K 1,14 mln. 1,05 mln. | Marktkapitalisatie | 17,71 mln. 22,55 mln. 20,81 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -6 mln. -7,64 mln. -7,05 mln. | Nettowinst (verlies) 2023 | -7 mln. -8,91 mln. -8,23 mln. | EV/omzet 2022 | 8,33 x |
Nettoliquiditeiten 2022 | 3,01 mln. 3,84 mln. 3,54 mln. | Nettoliquiditeiten 2023 | 2,94 mln. 3,74 mln. 3,45 mln. | EV/omzet 2023 | 16,5 x |
K/w-verhouding 2022 |
-1,15
x | K/w-verhouding 2023 |
-1,88
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 50,93% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Avihu Tamir
CEO | Chief Executive Officer | - | - |
Assaf Vardimon
DFI | Director of Finance/CFO | 46 | - |
Ophir Shimshi
COO | Chief Operating Officer | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Ian Mattioli
CHM | Chairman | 62 | 09-05-23 |
David Tsur
BRD | Director/Board Member | 73 | 28-06-21 |
Sharon Malka
BRD | Director/Board Member | 51 | 04-05-23 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+38,51% | 727 mld. | |
+33,05% | 599 mld. | |
-6,23% | 354 mld. | |
+18,78% | 328 mld. | |
+1,35% | 277 mld. | |
+16,00% | 243 mld. | |
+8,09% | 205 mld. | |
-5,77% | 203 mld. | |
+6,19% | 164 mld. |